Reuters -- Anglo-Swedish drugmaker AstraZeneca is aggressively meeting potential acquisition partners as it prepares for generic competition from some of its best-selling drugs.
Reuters -- Anglo-Swedish drugmaker AstraZeneca is aggressively meeting potential acquisition partners as it prepares for generic competition from some of its best-selling drugs.